BioWorld
-
Foghorn lands $425M oncology deal with Merck
-
Velosbio raises $137M series B for ROR1-targeting cancer therapies
-
Osivax secures $36M in grant, equity funding for flu, coronavirus vaccine programs
-
Today's news in brief
-
Varmx adds $36M to advance universal anticoagulant antidote
-
AIDS2020: Virtual: Can state of the ART get to ‘see you next year’?
-
Partisan votes on U.S. federal agency appropriations foreshadow showdown between House, Senate
-
The need for speed: Novavax receives $1.6B in Operation Warp Speed funding
-
To B or not to B: Corvus’ new approach takes arms against COVID-19
BioWorld MedTech
-
Doctor On Demand raises $75M in series D
-
U.S. FDA urges test developers to amend EUAs for pooled sample testing
-
Today's news in brief
-
Nonin nabs FDA nod for wireless handheld for first responders to monitor oxygen indicators
-
BioWorld MedTech’s Orthopedics Extra for July 8, 2020
-
Court approves first step in Endologix reorganization, agreement with Deerfield Partners to take company private
-
AI-powered stroke imaging solution nabs CADx clearance
-
FDA gives breakthrough nod to Dascena’s predictive algorithm for acute kidney injury
-
Residuals a point of special concern for FDA in N95 mask reprocessing
BioWorld Asia
-
Japan’s MLWH ends June with string of approvals, looks set for busy 2H 2020
-
SK Biopharma continues to glow after successful listing
-
News in brief
-
HKEX gains Ocumension as its fifth biotech IPO this year
-
COVID-19: Trying for herd immunity without vaccine ‘unethical’ and ‘unachievable’
-
Snowballing research preps avalanche to bury COVID-19
-
Carmine inks $900M+ deal to develop nonviral gene therapies for Takeda
-
Immunotech plans to raise $142M on HKEX to advance AAL therapy for liver cancer
-
Denovo closes $83.5M series C round to support phase III trials of enzastaurin
